Literature DB >> 12162444

Arsenic carcinogenicity: relevance of c-Src activation.

Petia P Simeonova1, Michael I Luster.   

Abstract

Environmental and occupational exposure to arsenic is associated with increased risk of skin, urinary bladder and respiratory tract cancers. Increasing evidence indicates that arsenic acts at the level of tumor promotion by modulating the signaling pathways responsible for cell growth. One of this pathways might include c-Src dependent EGFR and MAPK activation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12162444

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  57 in total

1.  c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation.

Authors:  K Chen; J A Vita; B C Berk; J F Keaney
Journal:  J Biol Chem       Date:  2001-02-27       Impact factor: 5.157

Review 2.  Arsenic and the skin.

Authors:  R A Schwartz
Journal:  Int J Dermatol       Date:  1997-04       Impact factor: 2.736

3.  Nonlinearity in the lung cancer dose-response for airborne arsenic: apparent confounding by year of hire in evaluating lung cancer risks from arsenic exposure in Tacoma smelter workers.

Authors:  J Viren; A Silvers
Journal:  Regul Toxicol Pharmacol       Date:  1999-10       Impact factor: 3.271

Review 4.  Vascular effects of chronic arsenic exposure: a review.

Authors:  R R Engel; C Hopenhayn-Rich; O Receveur; A H Smith
Journal:  Epidemiol Rev       Date:  1994       Impact factor: 6.222

5.  Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation.

Authors:  P P Simeonova; S Wang; W Toriuma; V Kommineni; J Matheson; N Unimye; F Kayama; D Harki; M Ding; V Vallyathan; M I Luster
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Authors:  D A Tice; J S Biscardi; A L Nickles; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Bladder cancer mortality associated with arsenic in drinking water in Argentina.

Authors:  C Hopenhayn-Rich; M L Biggs; A Fuchs; R Bergoglio; E E Tello; H Nicolli; A H Smith
Journal:  Epidemiology       Date:  1996-03       Impact factor: 4.822

9.  Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: relevance to arsenic carcinogenesis.

Authors:  J L Brown; K T Kitchin
Journal:  Cancer Lett       Date:  1996-01-02       Impact factor: 8.679

Review 10.  Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways.

Authors:  G Carpenter
Journal:  J Cell Biol       Date:  1999-08-23       Impact factor: 10.539
View more
  9 in total

1.  Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Authors:  Christina Michailidi; Masamichi Hayashi; Sayantan Datta; Tanusree Sen; Kaitlyn Zenner; Oluwadamilola Oladeru; Mariana Brait; Evgeny Izumchenko; Alexander Baras; Christopher VandenBussche; Maria Argos; Trinity J Bivalacqua; Habibul Ahsan; Noah M Hahn; George J Netto; David Sidransky; Mohammad Obaidul Hoque
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

2.  Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells.

Authors:  Todd A Stueckle; Yongju Lu; Mary E Davis; Liying Wang; Bing-Hua Jiang; Ida Holaskova; Rosana Schafer; John B Barnett; Yon Rojanasakul
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-13       Impact factor: 4.219

3.  Chronic arsenic exposure suppresses ATM pathway activation in human keratinocytes.

Authors:  Alexandra N Nail; Lakynkalina M McCaffrey; Mayukh Banerjee; Ana P Ferragut Cardoso; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2022-05-02       Impact factor: 4.460

4.  Arsenic Stimulates Myoblast Mitochondrial Epidermal Growth Factor Receptor to Impair Myogenesis.

Authors:  Amin Cheikhi; Teresa Anguiano; Jane Lasak; Baoli Qian; Amrita Sahu; Hikaru Mimiya; Charles C Cohen; Peter Wipf; Fabrisia Ambrosio; Aaron Barchowsky
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

5.  Arsenic alters vascular smooth muscle cell focal adhesion complexes leading to activation of FAK-src mediated pathways.

Authors:  Michele D Pysher; Qin M Chen; Richard R Vaillancourt
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-11       Impact factor: 4.219

Review 6.  Arsenic and Human Health: Genotoxicity, Epigenomic Effects, and Cancer Signaling.

Authors:  Munir Ozturk; Mert Metin; Volkan Altay; Rouf Ahmad Bhat; Mahnoor Ejaz; Alvina Gul; Bengu Turkyilmaz Unal; Mirza Hasanuzzaman; Lutfunnahar Nibir; Kamuran Nahar; Andleep Bukhari; Moonisa Aslam Dervash; Tomonori Kawano
Journal:  Biol Trace Elem Res       Date:  2021-04-16       Impact factor: 3.738

Review 7.  The Role of Reactive Oxygen Species in Arsenic Toxicity.

Authors:  Yuxin Hu; Jin Li; Bin Lou; Ruirui Wu; Gang Wang; Chunwei Lu; Huihui Wang; Jingbo Pi; Yuanyuan Xu
Journal:  Biomolecules       Date:  2020-02-05

Review 8.  Molecular features in arsenic-induced lung tumors.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey Ss Enfield; David Rowbotham; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Mol Cancer       Date:  2013-03-19       Impact factor: 27.401

9.  Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.

Authors:  Kushtrim Kryeziu; Christine Pirker; Bernhard Englinger; Sushilla van Schoonhoven; Melanie Spitzwieser; Thomas Mohr; Wilfried Körner; Regina Weinmüllner; Koray Tav; Johannes Grillari; Margit Cichna-Markl; Walter Berger; Petra Heffeter
Journal:  Oncotarget       Date:  2016-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.